Taken from Amgen's earning call transcript. Novel Delivery Systems????????????? RRM
We continue to invest strategically in Enbrel, including pursuit of new indications and "novel delivery"" systems to enhance the value it brings to patients and providers. Given its long period of patent protection, Enbrel will continue to generate significant cash flows for many years to come.
- Forums
- ASX - By Stock
- UNS
- Amgen transcript line
Amgen transcript line
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online